Terms: = Lung cancer AND BTG1, P62324, 694, ENSG00000133639 AND Treatment
60 results:
1. Association of Timely Comprehensive Genomic Profiling With Precision Oncology treatment Use and Patient Outcomes in Advanced Non-Small-Cell lung cancer.
Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
[TBL] [Abstract] [Full Text] [Related]
2. Ct-based subregional radiomics using hand-crafted and deep learning features for prediction of therapeutic response to anti-PD1 therapy in NSCLC.
Hu Y; Jiang T; Wang H; Song J; Yang Z; Wang Y; Su J; Jin M; Chang S; Deng K; Jiang W
Phys Med; 2024 Jan; 117():103200. PubMed ID: 38160516
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of primary and metastatic site-related PD-L1 expression in predicting ORR in patients with advanced NSCLC who received ICB-based therapy.
Zhou D; Wang Y; Ning W; Chen C
Thorac Cancer; 2024 Feb; 15(5):379-385. PubMed ID: 38155421
[TBL] [Abstract] [Full Text] [Related]
4. A meta-analysis for the efficacy and safety of icotinib combined with radiotherapy in treating brain metastases of non-small cell lung cancer.
Zhang B
Medicine (Baltimore); 2023 Sep; 102(36):e34572. PubMed ID: 37682155
[TBL] [Abstract] [Full Text] [Related]
5. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI treatment in ALK-Rearranged Non-Small Cell lung cancer.
Zheng N; Zhang Y; Zeng Y; Ma Q; Zhang R; Zhao Q; Lu C; Tian J; Wang Z; Tang H; Luo N; Xiao H; He Y; Wu F; Li L
Target Oncol; 2023 Jul; 18(4):625-636. PubMed ID: 37351800
[TBL] [Abstract] [Full Text] [Related]
6. Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
Oh BC; Cho AR; Nam JH; Yang SY; Kim MJ; Kwon SH; Lee EK
BMC Cancer; 2023 May; 23(1):482. PubMed ID: 37248452
[TBL] [Abstract] [Full Text] [Related]
7. Immunotherapy with Autoimmune Complication in Renal cancer.
Sunil SP; Kumar S; Hussaini S; Kandula S
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116021
[TBL] [Abstract] [Full Text] [Related]
8. Routine practice data of three cancer entities: Comparison among cancer registry and health insurance data.
Lang LM; Behr C; Ludwig M; Walker J; Christian Lange H; Basedow F; Justenhoven C
Z Evid Fortbild Qual Gesundhwes; 2023 Apr; 177():65-72. PubMed ID: 36804770
[TBL] [Abstract] [Full Text] [Related]
9. The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy.
Zhang L; Zhao K; Kuang T; Wang K; Chai D; Qiu Z; Liu R; Deng W; Wang W
BMC Cancer; 2023 Jan; 23(1):101. PubMed ID: 36717809
[TBL] [Abstract] [Full Text] [Related]
10. [Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell
lung cancer Patients with Acquired EGFR T790M Mutation].
Gu Y; Tian X; Wang R; Li X; Qian K; Li Y; Nong J
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):843-851. PubMed ID: 36617470
[TBL] [Abstract] [Full Text] [Related]
11. Comparative proteomics reveals anticancer compounds from Lansium domesticum against NSCLC cells target mitochondrial processes.
Alvarez MR; De Juan F; Zhou Q; Dimzon IKD; Grijaldo SJ; Sunga S; Heralde F; Lebrilla CB; Completo GC; Nacario RC
Cell Biochem Funct; 2023 Mar; 41(2):166-176. PubMed ID: 36606472
[TBL] [Abstract] [Full Text] [Related]
12. Glucose metabolic heterogeneity correlates with pathological features and improves survival stratification of resectable lung adenocarcinoma.
Chen YH; Chen YC; Lue KH; Chu SC; Chang BS; Wang LY; Li MH; Lin CB
Ann Nucl Med; 2023 Feb; 37(2):139-150. PubMed ID: 36436112
[TBL] [Abstract] [Full Text] [Related]
13. Immunotherapy combined with chemotherapy versus chemotherapy alone as the first-line treatment of PD-L1-negative and driver-gene-negative advanced nonsquamous non-small-cell lung cancer: An updated systematic review and meta-analysis.
Chai Y; Wu X; Zou Y; Zhang X; Bai H; Dong M; Duan J
Thorac Cancer; 2022 Nov; 13(22):3124-3132. PubMed ID: 36168110
[TBL] [Abstract] [Full Text] [Related]
14. Network-Based Pharmacological Study on the Mechanism of Action of Buxue Liqi Huatan Decoction in the treatment of lung cancer.
Wei H; Zhou L; Zhao X; Xie F
Comput Intell Neurosci; 2022; 2022():3418687. PubMed ID: 36035842
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in lung cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract] [Full Text] [Related]
16. Surgical resection versus radiotherapy for clinical stage IA lung cancer ≤1 cm in size: A population-based study.
Huang W; Deng HY; Wu XN; Xu K; Li P; Lin MY; Yuan C; Zhou Q
Asian J Surg; 2023 Jan; 46(1):385-393. PubMed ID: 35525696
[TBL] [Abstract] [Full Text] [Related]
17. Is Clinical Research Serving the Needs of the Global cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials.
Dodkins J; Hopman WM; Wells JC; Lievens Y; Malik RA; Pramesh CS; Gyawali B; Hammad N; Mukherji D; Sullivan R; Parkes J; Booth CM; Aggarwal A
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):500-508. PubMed ID: 35151802
[TBL] [Abstract] [Full Text] [Related]
18. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract] [Full Text] [Related]
19. DASC-21: a novel geriatric assessment for discriminating best supportive care in older patients with inoperable advanced non-small cell lung cancer.
Yamamoto H; Sazuka M; Ishibashi M; Nogimori C; Takada K; Hamaya H; Yamada H; Awata S
Jpn J Clin Oncol; 2021 Nov; 51(11):1628-1635. PubMed ID: 34453179
[TBL] [Abstract] [Full Text] [Related]
20. Risk assessment of malignancy in solitary pulmonary nodules in lung computed tomography: a multivariable predictive model study.
Liu HY; Zhao XR; Chi M; Cheng XS; Wang ZQ; Xu ZW; Li YL; Yang R; Wu YJ; Zhang XJ
Chin Med J (Engl); 2021 Jun; 134(14):1687-1694. PubMed ID: 34397595
[TBL] [Abstract] [Full Text] [Related]
[Next]
